BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 20525756)

  • 1. Safety, efficacy, pharmacokinetics, and pharmacodynamics of the combination of sorafenib and tanespimycin.
    Vaishampayan UN; Burger AM; Sausville EA; Heilbrun LK; Li J; Horiba MN; Egorin MJ; Ivy P; Pacey S; Lorusso PM
    Clin Cancer Res; 2010 Jul; 16(14):3795-804. PubMed ID: 20525756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma.
    Escudier B; Lassau N; Angevin E; Soria JC; Chami L; Lamuraglia M; Zafarana E; Landreau V; Schwartz B; Brendel E; Armand JP; Robert C
    Clin Cancer Res; 2007 Mar; 13(6):1801-9. PubMed ID: 17363536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study.
    Modi S; Stopeck AT; Gordon MS; Mendelson D; Solit DB; Bagatell R; Ma W; Wheler J; Rosen N; Norton L; Cropp GF; Johnson RG; Hannah AL; Hudis CA
    J Clin Oncol; 2007 Dec; 25(34):5410-7. PubMed ID: 18048823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma.
    Davies MA; Fox PS; Papadopoulos NE; Bedikian AY; Hwu WJ; Lazar AJ; Prieto VG; Culotta KS; Madden TL; Xu Q; Huang S; Deng W; Ng CS; Gupta S; Liu W; Dancey JE; Wright JJ; Bassett RL; Hwu P; Kim KB
    Clin Cancer Res; 2012 Feb; 18(4):1120-8. PubMed ID: 22223528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results of a phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer.
    Kupsch P; Henning BF; Passarge K; Richly H; Wiesemann K; Hilger RA; Scheulen ME; Christensen O; Brendel E; Schwartz B; Hofstra E; Voigtmann R; Seeber S; Strumberg D
    Clin Colorectal Cancer; 2005 Sep; 5(3):188-96. PubMed ID: 16197622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma.
    Pacey S; Gore M; Chao D; Banerji U; Larkin J; Sarker S; Owen K; Asad Y; Raynaud F; Walton M; Judson I; Workman P; Eisen T
    Invest New Drugs; 2012 Feb; 30(1):341-9. PubMed ID: 20683637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I trial to investigate the safety, pharmacokinetics and efficacy of sorafenib combined with docetaxel in patients with advanced refractory solid tumours.
    Awada A; Hendlisz A; Christensen O; Lathia CD; Bartholomeus S; Lebrun F; de Valeriola D; Brendel E; Radtke M; Delaunoit T; Piccart-Gebhart M; Gil T
    Eur J Cancer; 2012 Mar; 48(4):465-74. PubMed ID: 22285181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.
    Azad NS; Posadas EM; Kwitkowski VE; Steinberg SM; Jain L; Annunziata CM; Minasian L; Sarosy G; Kotz HL; Premkumar A; Cao L; McNally D; Chow C; Chen HX; Wright JJ; Figg WD; Kohn EC
    J Clin Oncol; 2008 Aug; 26(22):3709-14. PubMed ID: 18669456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
    Okamoto I; Miyazaki M; Morinaga R; Kaneda H; Ueda S; Hasegawa Y; Satoh T; Kawada A; Fukuoka M; Fukino K; Tanigawa T; Nakagawa K
    Invest New Drugs; 2010 Dec; 28(6):844-53. PubMed ID: 19760364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer.
    Solit DB; Ivy SP; Kopil C; Sikorski R; Morris MJ; Slovin SF; Kelly WK; DeLaCruz A; Curley T; Heller G; Larson S; Schwartz L; Egorin MJ; Rosen N; Scher HI
    Clin Cancer Res; 2007 Mar; 13(6):1775-82. PubMed ID: 17363532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib.
    Mross K; Steinbild S; Baas F; Gmehling D; Radtke M; Voliotis D; Brendel E; Christensen O; Unger C
    Eur J Cancer; 2007 Jan; 43(1):55-63. PubMed ID: 17095207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma.
    Larkin JM; Ferguson TR; Pickering LM; Edmonds K; James MG; Thomas K; Banerji U; Berns B; de Boer C; Gore ME
    Br J Cancer; 2010 Oct; 103(8):1149-53. PubMed ID: 20842130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma: New York Cancer Consortium Trial NCI 6981.
    Tagawa ST; Milowsky MI; Jeske S; Mazumdar M; Kung S; Sung M; Lehrer D; Matulich D; Selzer J; Wright JJ; Nanus DM
    Am J Clin Oncol; 2011 Oct; 34(5):443-8. PubMed ID: 20881475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I combination of sorafenib and erlotinib therapy in solid tumors: safety, pharmacokinetic, and pharmacodynamic evaluation from an expansion cohort.
    Quintela-Fandino M; Le Tourneau C; Duran I; Chen EX; Wang L; Tsao M; Bandarchi-Chamkhaleh B; Pham NA; Do T; MacLean M; Nayyar R; Tusche MW; Metser U; Wright JJ; Mak TW; Siu LL
    Mol Cancer Ther; 2010 Mar; 9(3):751-60. PubMed ID: 20197396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase IB study of sorafenib in combination with gemcitabine and cisplatin in patients with refractory solid tumors.
    Schultheis B; Kummer G; Zeth M; Brendel E; Xia C; Kornacker M; Strumberg D
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):333-9. PubMed ID: 21735354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sorafenib: a review of its use in advanced hepatocellular carcinoma.
    Keating GM; Santoro A
    Drugs; 2009; 69(2):223-40. PubMed ID: 19228077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors.
    Moore M; Hirte HW; Siu L; Oza A; Hotte SJ; Petrenciuc O; Cihon F; Lathia C; Schwartz B
    Ann Oncol; 2005 Oct; 16(10):1688-94. PubMed ID: 16006586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia.
    Kaufmann SH; Karp JE; Litzow MR; Mesa RA; Hogan W; Steensma DP; Flatten KS; Loegering DA; Schneider PA; Peterson KL; Maurer MJ; Smith BD; Greer J; Chen Y; Reid JM; Ivy SP; Ames MM; Adjei AA; Erlichman C; Karnitz LM
    Haematologica; 2011 Nov; 96(11):1619-26. PubMed ID: 21791475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of tanespimycin in combination with bortezomib in patients with advanced solid malignancies.
    Schenk E; Hendrickson AE; Northfelt D; Toft DO; Ames MM; Menefee M; Satele D; Qin R; Erlichman C
    Invest New Drugs; 2013 Oct; 31(5):1251-6. PubMed ID: 23543109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma.
    Reardon DA; Vredenburgh JJ; Desjardins A; Peters K; Gururangan S; Sampson JH; Marcello J; Herndon JE; McLendon RE; Janney D; Friedman AH; Bigner DD; Friedman HS
    J Neurooncol; 2011 Jan; 101(1):57-66. PubMed ID: 20443129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.